Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BMS-986213 Clear all
Recruiting Phase 2 Interventional

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

NCT05704647
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134
View directory record Official record
Conditions
Melanoma
Interventions
relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Anchorage, Alaska • Phoenix, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

NCT01968109
View directory record Official record
Conditions
Neoplasms by Site
Interventions
Relatlimab, Nivolumab, BMS-986213
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • Tampa, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

NCT03662659
View directory record Official record
Conditions
Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
Interventions
BMS-986213, Nivolumab, XELOX, FOLFOX, SOX
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
13
States / cities
Clovis, California • Duarte, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 3, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
View directory record Official record
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT06708949
View directory record Official record
Conditions
Renal Cell Carcinoma, Clear Cell
Interventions
Drugs Nivolumab, Ipilimumab, BMS-986213 (Relatlimab-Nivolumab FDC)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Durham, North Carolina • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab + Relatlimab, rHuPH20
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986482, Nivolumab and rHuPH20, Nivolumab/relatlimab/rHuPH20, Bevacizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Irvine, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

NCT05328908
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nivolumab-relatlimab FDC, Regorafenib, TAS-102
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Springdale, Arkansas • Los Angeles, California • Norwich, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Pan Tumor Rollover Study

NCT03899155
View directory record Official record
Conditions
Cancer
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
59
States / cities
Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 1:38 PM EDT
Withdrawn Phase 2 Interventional

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT03704077
View directory record Official record
Conditions
Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
Interventions
Relatlimab + Nivolumab, Nivolumab, Paclitaxel, Ramucirumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Daphne, Alabama • Bakersfield, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 3, 2026, 1:38 PM EDT